Kim Hyun-Young, Kim Jin Hyun, Jung Myeong Hee, Cho In Ae, Kim Youngjin, Cho Min-Chul
Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju 52727, Republic of Korea.
Biomedical Research Institute, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea.
Int J Endocrinol. 2019 Jan 13;2019:9120467. doi: 10.1155/2019/9120467. eCollection 2019.
Bioavailable 25-hydroxy vitamin D (25(OH)D) has been suggested for the accurate determination of vitamin D status. The purpose of this study was to determine the utility of bioavailable 25(OH)D in assessing vitamin D status when vitamin D-binding protein (VDBP) was significantly altered by pregnancy and liver cirrhosis (LC). The role of genotyping of , a gene encoding VDBP, in the determination of bioavailable 25(OH)D concentration in a Korean population was also evaluated.
This prospective study enrolled a total of 136 subjects (53 healthy controls, 45 patients with LC, and 38 pregnant women) from 2017 to 2018. The concentrations of total 25(OH)D and VDBP were measured, and bioavailable 25(OH)D concentrations were calculated. genotyping was performed to determine rs4588 and rs7041 polymorphisms. Clinical and laboratory data were compared among the three groups of subjects.
Median VDBP and total 25(OH)D concentrations were 165.2 g/ml and 18.5 ng/ml in healthy controls, 76.9 g/ml and 10.5 ng/ml in patients with LC, and 368.9 g/ml and 17.7 ng/ml in pregnant women, respectively. Compared with controls, patients diagnosed with LC had significantly lower VDBP and total 25(OH)D concentrations (all < 0.001) while pregnant women had significantly higher VDBP concentrations ( < 0.001). Although total 25(OH)D concentrations in pregnant women were similar to those in controls ( = 0.394), their bioavailable 25(OH)D concentrations were significantly lower (1.2 vs. 3.0 ng/ml; < 0.001). Among all the three groups combined, the genotype-specific bioavailable 25(OH)D and the genotype-independent bioavailable 25(OH)D concentrations did not differ significantly ( = 0.299).
Our study has demonstrated that bioavailable 25(OH)D concentration reflects vitamin D status more accurately than the total 25(OH)D concentration, especially in pregnant women. In addition, genotyping did not significantly affect bioavailable 25(OH)D concentration. Therefore, if VDBP concentration is significantly altered, the measurement of bioavailable 25(OH)D concentration might facilitate the accurate determination of vitamin D status. However, genotyping might be unnecessary.
生物可利用的25-羟基维生素D(25(OH)D)已被推荐用于准确测定维生素D状态。本研究的目的是确定当维生素D结合蛋白(VDBP)因妊娠和肝硬化(LC)而显著改变时,生物可利用的25(OH)D在评估维生素D状态中的效用。还评估了编码VDBP的基因的基因分型在韩国人群生物可利用的25(OH)D浓度测定中的作用。
这项前瞻性研究在2017年至2018年共纳入了136名受试者(53名健康对照者、45名LC患者和38名孕妇)。测量了总25(OH)D和VDBP的浓度,并计算了生物可利用的25(OH)D浓度。进行基因分型以确定rs4588和rs7041多态性。比较了三组受试者的临床和实验室数据。
健康对照者中VDBP和总25(OH)D浓度的中位数分别为165.2μg/ml和18.5ng/ml,LC患者中分别为76.9μg/ml和10.5ng/ml,孕妇中分别为368.9μg/ml和17.7ng/ml。与对照组相比,诊断为LC的患者VDBP和总25(OH)D浓度显著更低(均P<0.001),而孕妇的VDBP浓度显著更高(P<0.001)。尽管孕妇的总25(OH)D浓度与对照组相似(P=0.394),但其生物可利用的25(OH)D浓度显著更低(1.2 vs. 3.0ng/ml;P<0.001)。在合并的所有三组中,基因型特异性生物可利用的25(OH)D和非基因型依赖性生物可利用的25(OH)D浓度差异不显著(P=0.299)。
我们的研究表明,生物可利用的25(OH)D浓度比总25(OH)D浓度更准确地反映维生素D状态,尤其是在孕妇中。此外,基因分型对生物可利用的25(OH)D浓度没有显著影响。因此,如果VDBP浓度显著改变,测量生物可利用的25(OH)D浓度可能有助于准确测定维生素D状态。然而,基因分型可能没有必要。